SEC Comment Letter 0000000000-24-001932 to Whitehawk Therapeutics, Inc. (WHWK)
Whitehawk Therapeutics, Inc.
Date: Feb. 20, 2024 · CIK: 0001422142 · Accession: 0000000000-24-001932
AI Filing Summary & Sentiment
File numbers found in text: 333-277018
Letter
United States securities and exchange commission logo February 20, 2024 David Lennon Chief Executive Officer Aadi Bioscience, Inc. 17383 Sunset Boulevard Suite A250 Pacific Palisades, CA 90272 Re:Aadi Bioscience, Inc. Registration Statement on Form S-3 Filed February 12, 2024 File No. 333-277018 Dear David Lennon: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Cindy Polynice at 202-551-8707 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Robert Wernli, Esq.
Show Raw Text
United States securities and exchange commission logo
February 20, 2024
David Lennon
Chief Executive Officer
Aadi Bioscience, Inc.
17383 Sunset Boulevard Suite A250
Pacific Palisades, CA 90272
Re:Aadi Bioscience, Inc.
Registration Statement on Form S-3
Filed February 12, 2024
File No. 333-277018
Dear David Lennon:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Cindy Polynice at 202-551-8707 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Robert Wernli, Esq.